Tuberculosis (TB) is an infectious disease caused by the pathogen Mycobacterium tuberculosis (M. tuberculosis),
killing about two million people worldwide each year. An increase in the prevalence of drug-resistant strains of M. tuberculosis
in the past decades has renewed focus on the development of new drugs that can treat both drug-sensitive and resistant TB
infections. M. tuberculosis evades the host immune system and drug regimes by entering dormant phase within macrophage.
As a consequence, there is a pressing need for new vaccines and antimicrobials to treat persistent infections. As clinically
used antibiotics target very few essential functions of mycobacterium, it is rational that identification of new targets that are
essential for bacterial growth and survival can serve as starting point for designing of novel drugs to cure both drug-sensitive
and resistant TB infections. With the development of molecular biology and structural biology and the availability of the genome
sequence of M. tuberculosis, some success has been achieved in the identification of new targets in M. tuberculosis and
their relevant inhibitors. This review summarizes about ninety important targets that participate in a range of diverse physiological
processes in M. tuberculosis and seven new drugs currently in clinical phase 2 or 3 trials. In addition, promising inhibitors
with novel mechanisms of action and clinical vaccine candidates are highlighted.
Keywords: Antimycobacterial, dormant, drug-resistant, inhibitors, Mycobacterium tuberculosis, new targets.
Rights & PermissionsPrintExport
Published on: 30 April, 2013
Page: [676 - 699]